Tesamorelin 10MG

Tesamorelin (also known as Egrifta) is a synthetic 44-amino-acid analog of Growth Hormone-Releasing Hormone (GHRH). Unlike direct HGH administration, Tesamorelin works through the body’s own natural endocrine system by stimulating the pituitary gland to release endogenous growth hormone, which subsequently increases circulating IGF-1 levels. Among all growth hormone-related research peptides, Tesamorelin carries one of the strongest human clinical evidence bases available, having undergone large-scale randomized controlled trials and receiving FDA approval.

Primary Research Areas

Tesamorelin has been studied across several key scientific fields including growth hormone physiology, IGF-1 signaling, visceral fat reduction, HIV-associated lipodystrophy, metabolic health, fatty liver disease, body composition research, and endocrine regulation.

Key Research Findings

Clinical and preclinical research has demonstrated the following findings associated with Tesamorelin:

• Significant stimulation of endogenous growth hormone release through GHRH receptor activation
• Measurable increases in circulating IGF-1 levels across multiple human studies
• Substantial reductions in visceral adipose tissue (VAT) confirmed in large randomized controlled trials
• Improvements in waist circumference and abdominal fat distribution
• Preservation of lean body mass alongside visceral fat reduction
• Improvements in triglycerides, total cholesterol, and other metabolic markers
• Reductions in hepatic steatosis (liver fat accumulation) observed in more recent investigations
• FDA approval under the brand name Egrifta for reducing excess abdominal fat in adults with HIV-associated lipodystrophy

Mechanism of Action

Tesamorelin works through the following pathway:

GHRH Receptor Activation → Increased Endogenous GH Release → Elevated IGF-1 Production → Enhanced Lipolysis → Reduced Visceral Fat Accumulation

Because Tesamorelin stimulates the body’s own pituitary gland rather than directly introducing exogenous growth hormone, GH release remains under normal physiological feedback control, which is considered an important distinction in research settings.

Evidence Strength

Research Use Disclaimer

This product is supplied strictly for in vitro and laboratory research purposes only. It is not approved by the FDA for general use and is not intended for human consumption, therapeutic, diagnostic, or veterinary use. By purchasing this product, you confirm that you are a qualified researcher and that the compound will be used solely in a controlled research environment in accordance with all applicable laws and regulations.